Search Results - "Ripa, Steven R."

Efficacy and Safety of the Seven-Day Buprenorphine Transdermal System in Opioid-Naïve Patients with Moderate to Severe Chronic Low Back Pain: An Enriched, Randomized, Double-Blind, Placebo-Controlled Study by Steiner, Deborah J., MD, Sitar, Steve, MD, Wen, Warren, PhD, Sawyerr, Gosford, MA, Munera, Catherine, PhD, Ripa, Steven R., MD, Landau, Craig, MD

“…Abstract Context This article presents the results of a pivotal Phase 3 study that assesses a new treatment for the management of chronic low back pain: a…”
Get full text

Buprenorphine Transdermal Delivery System in Adults with Persistent Noncancer-Related Pain Syndromes Who Require Opioid Therapy: A Multicenter, 5-Week Run-in and Randomized, Double-Blind Maintenance-of-Analgesia Study by Landau, Craig J., MD, Carr, William D., MBChB, Razzetti, Albert J., MD, Sessler, Nelson E., PharmD, Munera, Catherine, PhD, Ripa, Steven R., MD

“…Abstract Objective: This study compared the efficacy and safety profile of buprenorphine transdermal delivery system (BTDS) and placebo in subjects with…”
Get full text

A multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of single-entity, once-daily hydrocodone tablets in patients with uncontrolled moderate to severe chronic low back pain by Wen, Warren, Sitar, Steve, Lynch, Shau Yu, He, Ellie, Ripa, Steven R

“…This multicenter, randomized, double-blind, placebo-controlled study with an enriched enrollment, randomized withdrawal design was conducted to evaluate the…”
Get more information

Hysingla® ER, a once-daily, single-entity hydrocodone with abuse-deterrent properties in treating chronic nonmalignant and nonneuropathic pain in patients with osteoarthritis by Taber, Louise, Baldridge, Stacy, He, Ellie, Ripa, Steven R.

“…Objectives: Osteoarthritis (OA)-related chronic pain is associated with physical and psychosocial impairment as well as poorer quality of life. There is…”
Get full text

Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trials by Harris, Stephen C., Morganroth, Joel, Ripa, Steven R., Thorn, Michael D., Colucci, Salvatore

“…Objectives: To study the effect of transdermal buprenorphine on QTc prolongation at dose levels of 10, 40, and 80 mcg/h, (BTDS 10, BTDS 40, BTDS 80). Methods:…”
Get full text

Evaluation of the Ototoxicity Potential of Once-Daily, Single-Entity Hydrocodone in Patients with Chronic Pain: Results of Two Phase-3 Clinical Studies by Campbell, Kathleen, Kutz, Jr, J Walter, Shoup, Angela, Wen, Warren, Lynch, Shau Yu, He, Ellie, Ripa, Steven R

“…Use/misuse of the opioid combination hydrocodone-acetaminophen has been associated with permanent hearing loss. Although reports have been rare, this potential…”
Get full text

Safety of buprenorphine transdermal system in the management of pain in older adults by Pergolizzi, Joseph V., Raffa, Robert B., Marcum, Zachary, Colucci, Salvatore, Ripa, Steven R.

“…Objectives: To evaluate whether buprenorphine transdermal system (BTDS; Butrans®) is an option for the treatment of chronic pain in older adults. Methods: This…”
Get full text

Long-term safety and effectiveness of once-daily, single-entity, extended-release hydrocodone over 76 weeks of an open-label study in patients with chronic noncancer and nonneuropathic pain by Taber, Louise, Lynch, Shau Yu, He, Ellie, Ripa, Steven R.

“…Objective: To evaluate long-term use of Hysingla ® ER (HYD), a single-entity, extended-release, once-daily hydrocodone bitartrate tablet with abuse-deterrent…”
Get full text

The Impact of Buprenorphine Transdermal Delivery System on Activities of Daily Living Among Patients With Chronic Low Back Pain: An Application of the International Classification of Functioning, Disability and Health by Miller, Kate, Yarlas, Aaron, Wen, Warren, Dain, Bradley, Lynch, Shau Yu, Ripa, Steven R, Pergolizzi, Joseph V, Raffa, Robert

“…OBJECTIVES:The Buprenorphine Transdermal Delivery System (BTDS) is indicated for reduction of pain in moderate to severe chronic low back pain (CLBP), which…”
Get full text

Buprenorphine Transdermal System Improves Sleep Quality and Reduces Sleep Disturbance in Patients with Moderate-to-Severe Chronic Low Back Pain: Results from Two Randomized Controlled Trials by Yarlas, Aaron, Miller, Kate, Wen, Warren, Lynch, Shau Yu, Ripa, Steven R., Pergolizzi, Joseph V., Raffa, Robert B.

“…Objective To evaluate the impact of buprenorphine (Butrans®) transdermal System (BTDS) treatment on sleep outcomes for patients with moderate‐to‐severe chronic…”
Get full text

Safety and effectiveness of once-daily Hysingla extended-release tablets in patients with baseline depression or anxiety by Taber, Louise, He, Ellie, Ripa, Steven R

“…Long-term safety and effectiveness of a once-daily, single-entity, extended-release formulation of hydrocodone bitartrate (HYD) for the treatment of moderate…”
Get full text

A randomized, placebo-controlled study of the impact of the 7-day buprenorphine transdermal system on health-related quality of life in opioid-naïve patients with moderate-to-severe chronic low back pain by Yarlas, Aaron, Miller, Kate, Wen, Warren, Dain, Bradley, Lynch, Shau Yu, Pergolizzi, Joseph V, Raffa, Robert B, Ripa, Steven R

“…This study evaluated the impact of treatment with Buprenorphine Transdermal System (BTDS) on the health-related quality of life for patients with…”
Get more information

Use of immediate-release opioids as supplemental analgesia during management of moderate-to-severe chronic pain with buprenorphine transdermal system by Silverman, Sanford, Raffa, Robert B, Cataldo, Marc J, Kwarcinski, Monica, Ripa, Steven R

“…The buprenorphine transdermal system (BTDS) is approved in the US for the management of chronic pain. Due to its high affinity for μ-opioid receptors with a…”
Get full text

Poster 151 Evaluation of the Effectiveness of Once-Daily Hydrocodone in Patient Subgroups by Wen, Warren, Lynch, Shau Yu, PhD, He, Ellie, PhD, Ripa, Steven R., MD

Get full text

Application site adverse events associated with the buprenorphine transdermal system: a pooled analysis by Wen, Warren, Lynch, Shau Yu, Munera, Catherine, Swanton, Ruth, Ripa, Steven R, Maibach, Howard

“…To characterize the profile of application site reactions (ASRs) for patients treated with the buprenorphine transdermal system (BTDS) in chronic pain studies…”
Get more information

A Subgroup Analysis Found no Diminished Response to Buprenorphine Transdermal System Treatment for Chronic Low Back Pain Patients Classified with Depression by Yarlas, Aaron, Miller, Kate, Wen, Warren, Lynch, Shau Yu, Munera, Catherine, Dain, Bradley, Pergolizzi Jr, Joseph V., Raffa, Robert, Ripa, Steven R.

“…Background Chronic pain (CP) patients with depression typically exhibit worse post‐treatment outcomes than nondepressed CP patients. The cause is often assumed…”
Get full text

Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain by Miller, Kate, Yarlas, Aaron, Wen, Warren, Dain, Bradley, Lynch, Shau Yu, Brennan, Michael J, Ripa, Steven R

“…To evaluate the impact of 12 weeks of treatment with Butrans® (buprenorphine) transdermal system (BTDS) on the health-related quality of life (HRQoL) for…”
Get more information

Buprenorphine transdermal system compared with placebo reduces interference in functioning for chronic low back pain by Yarlas, Aaron, Miller, Kate, Wen, Warren, Lynch, Shau Yu, Munera, Catherine, Pergolizzi, Joseph V., Raffa, Robert, Ripa, Steven R.

“…Objective: This study examines the efficacy of the buprenorphine transdermal system (BTDS) for reducing the interference of pain on physical and emotional…”
Get full text

A randomized, 14-day, double-blind study evaluating conversion from hydrocodone/acetaminophen (Vicodin) to buprenorphine transdermal system 10 μg/h or 20 μg/h in patients with osteoarthritis pain by Ripa, Steven R, McCarberg, Bill H, Munera, Catherine, Wen, Warren, Landau, Craig J

“…The objective of this study was to evaluate continued pain control and tolerability of converting patients from Vicodin (hydrocodone/acetaminophen; HCD/APAP)…”
Get more information

Survey of Treatment Satisfaction with Butrans™ (buprenorphine) Transdermal System by Wen, Warren, PhD, Lynch, Shau Yu, PhD, Munera, Catherine, PhD, Ripa, Steven R., MD

Get full text